Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer

J. E. Krook, J. N. Ingle, S. J. Green, W. D. Bowman, L. K. Everson, H. E. Windschitl, R. F. Marschke, J. A. Laurie, S. A. Cullinan, D. M. Pfeifle

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The purpose of this study was to determine if tamoxifen added to the efficacy of a CFP (cyclophosphamide, 5-FU, and prednisone) regimen. One hundred thirty-one postmenopausal women with advanced breast cancer without prior chemotherapy exposure were randomized to receive CFP alone or combined with tamoxifen; six were disqualified because of ineligibility. Objective responses were seen in 68% of the eligible patients receiving CFP and in 61% of those receiving CFP plus tamoxifen. Median times to progression were 287 days for CFP and 158 days for CFP plus tamoxifen (two-sided log-rank test of equality of progression distributions, P = 0.07). Median survival times were 544 days for CFP and 394 for CFP plus tamoxifen (two-sided log-rank test of equality of survival distributions, P = 0.08, after adjustment for stratification factors using the Cox model, two-sided P = 0.14). The addition of tamoxifen to CFP was not associated with longer time to progression or survival in any Cox covariate model. On the basis of our data, it can be concluded that the addition of tamoxifen to CFP does not substantially improve either the time to disease progression or survival in women with metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)355-361
Number of pages7
JournalCancer Treatment Reports
Volume69
Issue number4
StatePublished - 1985

Fingerprint

Tamoxifen
Prednisone
Fluorouracil
Cyclophosphamide
Randomized Controlled Trials
Breast Neoplasms
Survival
Proportional Hazards Models
Disease Progression
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Krook, J. E., Ingle, J. N., Green, S. J., Bowman, W. D., Everson, L. K., Windschitl, H. E., ... Pfeifle, D. M. (1985). Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. Cancer Treatment Reports, 69(4), 355-361.

Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. / Krook, J. E.; Ingle, J. N.; Green, S. J.; Bowman, W. D.; Everson, L. K.; Windschitl, H. E.; Marschke, R. F.; Laurie, J. A.; Cullinan, S. A.; Pfeifle, D. M.

In: Cancer Treatment Reports, Vol. 69, No. 4, 1985, p. 355-361.

Research output: Contribution to journalArticle

Krook, JE, Ingle, JN, Green, SJ, Bowman, WD, Everson, LK, Windschitl, HE, Marschke, RF, Laurie, JA, Cullinan, SA & Pfeifle, DM 1985, 'Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer', Cancer Treatment Reports, vol. 69, no. 4, pp. 355-361.
Krook, J. E. ; Ingle, J. N. ; Green, S. J. ; Bowman, W. D. ; Everson, L. K. ; Windschitl, H. E. ; Marschke, R. F. ; Laurie, J. A. ; Cullinan, S. A. ; Pfeifle, D. M. / Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 4. pp. 355-361.
@article{dc36f355d43440e7bf941677b56b75bd,
title = "Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer",
abstract = "The purpose of this study was to determine if tamoxifen added to the efficacy of a CFP (cyclophosphamide, 5-FU, and prednisone) regimen. One hundred thirty-one postmenopausal women with advanced breast cancer without prior chemotherapy exposure were randomized to receive CFP alone or combined with tamoxifen; six were disqualified because of ineligibility. Objective responses were seen in 68{\%} of the eligible patients receiving CFP and in 61{\%} of those receiving CFP plus tamoxifen. Median times to progression were 287 days for CFP and 158 days for CFP plus tamoxifen (two-sided log-rank test of equality of progression distributions, P = 0.07). Median survival times were 544 days for CFP and 394 for CFP plus tamoxifen (two-sided log-rank test of equality of survival distributions, P = 0.08, after adjustment for stratification factors using the Cox model, two-sided P = 0.14). The addition of tamoxifen to CFP was not associated with longer time to progression or survival in any Cox covariate model. On the basis of our data, it can be concluded that the addition of tamoxifen to CFP does not substantially improve either the time to disease progression or survival in women with metastatic breast cancer.",
author = "Krook, {J. E.} and Ingle, {J. N.} and Green, {S. J.} and Bowman, {W. D.} and Everson, {L. K.} and Windschitl, {H. E.} and Marschke, {R. F.} and Laurie, {J. A.} and Cullinan, {S. A.} and Pfeifle, {D. M.}",
year = "1985",
language = "English (US)",
volume = "69",
pages = "355--361",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer

AU - Krook, J. E.

AU - Ingle, J. N.

AU - Green, S. J.

AU - Bowman, W. D.

AU - Everson, L. K.

AU - Windschitl, H. E.

AU - Marschke, R. F.

AU - Laurie, J. A.

AU - Cullinan, S. A.

AU - Pfeifle, D. M.

PY - 1985

Y1 - 1985

N2 - The purpose of this study was to determine if tamoxifen added to the efficacy of a CFP (cyclophosphamide, 5-FU, and prednisone) regimen. One hundred thirty-one postmenopausal women with advanced breast cancer without prior chemotherapy exposure were randomized to receive CFP alone or combined with tamoxifen; six were disqualified because of ineligibility. Objective responses were seen in 68% of the eligible patients receiving CFP and in 61% of those receiving CFP plus tamoxifen. Median times to progression were 287 days for CFP and 158 days for CFP plus tamoxifen (two-sided log-rank test of equality of progression distributions, P = 0.07). Median survival times were 544 days for CFP and 394 for CFP plus tamoxifen (two-sided log-rank test of equality of survival distributions, P = 0.08, after adjustment for stratification factors using the Cox model, two-sided P = 0.14). The addition of tamoxifen to CFP was not associated with longer time to progression or survival in any Cox covariate model. On the basis of our data, it can be concluded that the addition of tamoxifen to CFP does not substantially improve either the time to disease progression or survival in women with metastatic breast cancer.

AB - The purpose of this study was to determine if tamoxifen added to the efficacy of a CFP (cyclophosphamide, 5-FU, and prednisone) regimen. One hundred thirty-one postmenopausal women with advanced breast cancer without prior chemotherapy exposure were randomized to receive CFP alone or combined with tamoxifen; six were disqualified because of ineligibility. Objective responses were seen in 68% of the eligible patients receiving CFP and in 61% of those receiving CFP plus tamoxifen. Median times to progression were 287 days for CFP and 158 days for CFP plus tamoxifen (two-sided log-rank test of equality of progression distributions, P = 0.07). Median survival times were 544 days for CFP and 394 for CFP plus tamoxifen (two-sided log-rank test of equality of survival distributions, P = 0.08, after adjustment for stratification factors using the Cox model, two-sided P = 0.14). The addition of tamoxifen to CFP was not associated with longer time to progression or survival in any Cox covariate model. On the basis of our data, it can be concluded that the addition of tamoxifen to CFP does not substantially improve either the time to disease progression or survival in women with metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021907567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021907567&partnerID=8YFLogxK

M3 - Article

C2 - 3888386

AN - SCOPUS:0021907567

VL - 69

SP - 355

EP - 361

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -